168 related articles for article (PubMed ID: 34397130)
41. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
42. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
43. Neuroendocrine tumors: novel approaches in the age of targeted therapy.
Phan AT; Yao JC
Oncology (Williston Park); 2008 Dec; 22(14):1617-23; discussion 1623-4, 1629. PubMed ID: 19198220
[TBL] [Abstract][Full Text] [Related]
44. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
45. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
46. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
[TBL] [Abstract][Full Text] [Related]
47. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
48. A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.
Martorana F; Colombo I; Treglia G; Gillessen S; Stathis A
Cancer Treat Rev; 2021 Dec; 101():102300. PubMed ID: 34688105
[TBL] [Abstract][Full Text] [Related]
49. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
50. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
51. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
53. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
Mick R; Crowley JJ; Carroll RJ
Control Clin Trials; 2000 Aug; 21(4):343-59. PubMed ID: 10913809
[TBL] [Abstract][Full Text] [Related]
54. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
55. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
Sivendran S; Newport K; Horst M; Albert A; Galsky MD
Trials; 2015 Aug; 16():341. PubMed ID: 26253548
[TBL] [Abstract][Full Text] [Related]
56. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
[TBL] [Abstract][Full Text] [Related]
57. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
58. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
59. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll KJ
J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
[TBL] [Abstract][Full Text] [Related]
60. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]